Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Martin Reck

Showing results (201-210 of 437) with videos related to

Pageof 44
Sort By:
Current Medical Research and Opinion|August 12, 2020
Patient-reported outcomes in RELAY, a phase 3 trial of ramucirumab plus erlotinib versus placebo plus erlotinib in untreated <i>EGFR</i>-mutated metastatic non-small-cell lung cancerKiyotaka Yoh, Shinji Atagi, Martin Reck, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 29, 2011
Randomized phase III placebo-controlled trial of carboplatin and paclitaxel with or without the vascular disrupting agent vadimezan (ASA404) in advanced non-small-cell lung cancerPrimo N Lara, Jean-Yves Douillard, Kazuhiko Nakagawa, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 17, 2016
Examining Treatment Outcomes with Erlotinib in Patients with Advanced Non-Small Cell Lung Cancer Whose Tumors Harbor Uncommon EGFR MutationsBarbara Klughammer, Wolfram Brugger, Federico Cappuzzo, et al.
Future Oncology (London, England)|February 14, 2019
Defining aggressive or early progressing nononcogene-addicted non-small-cell lung cancer: a separate disease entity?Martin Reck, Keith M Kerr, Christian Grohé, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|May 17, 2012
Tasisulam sodium (LY573636 sodium) as third-line treatment in patients with unresectable, metastatic non-small-cell lung cancer: a phase-II studyGiorgio V Scagliotti, Robert Ilaria, Silvia Novello, et al.
Journal of Hematology & Oncology|June 24, 2023
Emerging therapies targeting the delta-like ligand 3 (DLL3) in small cell lung cancerCharles M Rudin, Martin Reck, Melissa L Johnson, et al.
Clinical Medicine Insights. Oncology|September 5, 2020
Efficacy of Docetaxel Plus Ramucirumab as Palliative Third-Line Therapy Following Second-Line Immune-Checkpoint-Inhibitor Treatment in Patients With Non-Small-Cell Lung Cancer Stage IVWolfgang M Brueckl, Martin Reck, Achim Rittmeyer, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 17, 2007
A randomized phase II pharmacokinetic and pharmacodynamic study of indisulam as second-line therapy in patients with advanced non-small cell lung cancerDenis C Talbot, Joachim von Pawel, Emma Cattell, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|October 23, 2020
Dual EGFR-VEGF Pathway Inhibition: A Promising Strategy for Patients With EGFR-Mutant NSCLCXiuning Le, Monique Nilsson, Jonathan Goldman, et al.
Clinical Lung Cancer|November 30, 2016
Treatment Rationale and Study Design for the RELAY Study: A Multicenter, Randomized, Double-Blind Study of Erlotinib With Ramucirumab or Placebo in Patients With Epidermal Growth Factor Receptor Mutation-Positive Metastatic Non-Small-Cell Lung CancerEdward B Garon, Martin Reck, Luis Paz-Ares, et al.
Pageof 44

Showing results (201-210 of 437) with videos related to

Sort By:
Pageof 44
Current Medical Research and Opinion|August 12, 2020
Patient-reported outcomes in RELAY, a phase 3 trial of ramucirumab plus erlotinib versus placebo plus erlotinib in untreated <i>EGFR</i>-mutated metastatic non-small-cell lung cancerKiyotaka Yoh, Shinji Atagi, Martin Reck, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 29, 2011
Randomized phase III placebo-controlled trial of carboplatin and paclitaxel with or without the vascular disrupting agent vadimezan (ASA404) in advanced non-small-cell lung cancerPrimo N Lara, Jean-Yves Douillard, Kazuhiko Nakagawa, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 17, 2016
Examining Treatment Outcomes with Erlotinib in Patients with Advanced Non-Small Cell Lung Cancer Whose Tumors Harbor Uncommon EGFR MutationsBarbara Klughammer, Wolfram Brugger, Federico Cappuzzo, et al.
Future Oncology (London, England)|February 14, 2019
Defining aggressive or early progressing nononcogene-addicted non-small-cell lung cancer: a separate disease entity?Martin Reck, Keith M Kerr, Christian Grohé, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|May 17, 2012
Tasisulam sodium (LY573636 sodium) as third-line treatment in patients with unresectable, metastatic non-small-cell lung cancer: a phase-II studyGiorgio V Scagliotti, Robert Ilaria, Silvia Novello, et al.
Journal of Hematology & Oncology|June 24, 2023
Emerging therapies targeting the delta-like ligand 3 (DLL3) in small cell lung cancerCharles M Rudin, Martin Reck, Melissa L Johnson, et al.
Clinical Medicine Insights. Oncology|September 5, 2020
Efficacy of Docetaxel Plus Ramucirumab as Palliative Third-Line Therapy Following Second-Line Immune-Checkpoint-Inhibitor Treatment in Patients With Non-Small-Cell Lung Cancer Stage IVWolfgang M Brueckl, Martin Reck, Achim Rittmeyer, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 17, 2007
A randomized phase II pharmacokinetic and pharmacodynamic study of indisulam as second-line therapy in patients with advanced non-small cell lung cancerDenis C Talbot, Joachim von Pawel, Emma Cattell, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|October 23, 2020
Dual EGFR-VEGF Pathway Inhibition: A Promising Strategy for Patients With EGFR-Mutant NSCLCXiuning Le, Monique Nilsson, Jonathan Goldman, et al.
Clinical Lung Cancer|November 30, 2016
Treatment Rationale and Study Design for the RELAY Study: A Multicenter, Randomized, Double-Blind Study of Erlotinib With Ramucirumab or Placebo in Patients With Epidermal Growth Factor Receptor Mutation-Positive Metastatic Non-Small-Cell Lung CancerEdward B Garon, Martin Reck, Luis Paz-Ares, et al.
Pageof 44